The overall scientific goal of the Growth Control and Genomic Stability Program is to understand mechanisms of proliferation, transcriptional regulation of oncogenic signaling pathways, DNA damage response and checkpoint activation, maintenance of genomic integrity and telomere function, and how these processes are disrupted or altered in cancer cells. Genomic instability is one of the key contributors to cancer progression and the genesis of tumor heterogeneity, and can engender either sensitivity or resistance to targeted and dastogenic cancer therapies. The members of this program study diverse aspects of how normal somatic cells, stem cells, and cancer cells respond to DNA damage, maintain genomic integrity, and respond to traditional and targeted chemotherapies. The functions of p53 in cell cycle checkpoint control and in diverse stress responses, and the use of adenovirus early proteins to interrogate cell signaling pathways and p53 checkpoint signaling comprise areas of significant focus of the program with opportunities for clinical translation. Chemical genetics is being used to study cellular signaling pathways that drive cancer cell proliferation. Other important topics include molecular mechanisms of transcriptional regulation of oncogenic pathways and of tumor suppressor gene expression, how nuclear pore subunits regulate gene expression, and the relationship of fetal mammary stem cells to stem-like cells in breast cancer. The program includes nine members from five different Laboratories (Departments), see the following page for a list of personnel. The NCI and other peer-reviewed cancer related support (direct costs) for the last budget year was $3,049,383. The substantial NIH and other federal support for this program is outlined in the table of externally funded research projects. The total number of cancer-relevant publications by members of this program in the last grant period (2008- 2012) was 132. Of the total publications, 1% were intraprogrammatic and 13% were interprogrammatic.
The major hallmark of cancer is loss of the control of cell growth. This program will study the mechanisms by which cancer cells lose control, focusing in particular on mechanisms of controlling the stability of the cell genome.
|Evan, Gerard I; Hah, Nasun; Littlewood, Trevor D et al. (2017) Re-engineering the Pancreas Tumor Microenvironment: A ""Regenerative Program"" Hacked. Clin Cancer Res 23:1647-1655|
|Liu, Hao; Naxerova, Kamila; Pinter, Matthias et al. (2017) Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 23:5959-5969|
|Gasser, Emanuel; Moutos, Christopher P; Downes, Michael et al. (2017) FGF1 - a new weapon to control type 2 diabetes mellitus. Nat Rev Endocrinol 13:599-609|
|Chen, Peiwen; Zuo, Hao; Xiong, Hu et al. (2017) Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc Natl Acad Sci U S A 114:580-585|
|Manoogian, Emily N C; Panda, Satchidananda (2017) Circadian rhythms, time-restricted feeding, and healthy aging. Ageing Res Rev 39:59-67|
|Fan, Weiwei; Waizenegger, Wanda; Lin, Chun Shi et al. (2017) PPAR? Promotes Running Endurance by Preserving Glucose. Cell Metab 25:1186-1193.e4|
|Tufail, Yusuf; Cook, Daniela; Fourgeaud, Lawrence et al. (2017) Phosphatidylserine Exposure Controls Viral Innate Immune Responses by Microglia. Neuron 93:574-586.e8|
|Li, Dongming; Palanca, Ana Marie S; Won, So Youn et al. (2017) The MBD7 complex promotes expression of methylated transgenes without significantly altering their methylation status. Elife 6:|
|Wu, Min-Zu; Cheng, Wei-Chung; Chen, Su-Feng et al. (2017) miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS. Nat Cell Biol 19:1286-1296|
|Doktorova, Marcela; Zwarts, Irene; Zutphen, Tim van et al. (2017) Intestinal PPAR? protects against diet-induced obesity, insulin resistance and dyslipidemia. Sci Rep 7:846|
Showing the most recent 10 out of 429 publications